BridgeMD
PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis.
EU CTIS ID: 2023-503686-26-02
What this study is testing
To test the feasibility of differentiating predominant active fibrosis and predominant inflammation using PET imaging with FAPI in patients with PPF.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- ≥ 18 years of age
- New diagnosis of PPF
- A minimum of 20% of lung parenchyma is aberrant (fibrosis, inflammation or both)
- MDT indication for treatment with either immunosuppressive drugs or antifibrotic drug
You likely can't join if
- Prior or current treatment with antifibrotic drugs
- Active malignancy
- Inability to undergo a PET/CT at the Sint Antonius Hospital
- Incapacity to give informed consent personally
- Pregnancy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.